Advertisement

Measuring the Effects of Medication for Individuals with Autism

  • Jennifer ZarconeEmail author
  • Annette Griffith
  • Chrystal Jansz Rieken
Chapter

Abstract

Psychotropic medication is often prescribed for individuals with autism spectrum disorders (ASD) for a variety of behavioral concerns. These concerns can include problem behaviors such as aggression, self-injury, or property destruction, as well as repetitive and compulsive behavior. Other concerns such as impulsivity, inattentiveness, and mood disturbances may also be targeted by psychotropic medication. Unfortunately, medical providers often have to rely on caregivers to report changes in behavioral outcomes rather than gathering the information directly from the person taking the medication. Thus, the goal of this chapter is to help guide clinicians and educators to work collaboratively with medical providers to assist in measuring the effects of medications on the behavior targeted. In addition, information on collateral effects of the medication on other behaviors as well as side effects of medication can be monitored. Information on the drug development process, physiological measures that can be used to assess therapeutic outcomes, and tools for clinicians and families to use to measure medication effects are also described. Finally, guidelines for enhancing collaboration between patients, families, educators, and providers on treatment plan development are emphasized.

Keywords

Autism spectrum disorder Medications Effects Problem behaviors 

References

  1. Allen, M. H., Hirschfeld, R. M., Wozniak, P. J., Baker, J. D., & Bowden, C. L. (2006). Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. American Journal of Psychiatry, 163(2), 272–275.PubMedCrossRefPubMedCentralGoogle Scholar
  2. Alter, P. J., Conroy, M. A., Mancil, G., & Haydon, T. (2008). A comparison of functional behavior assessment methodologies with young children: Descriptive methods and functional analysis. Journal of Behavioral Education, 17(2), 200–219.CrossRefGoogle Scholar
  3. Aman, M., Novotny, S., Samango-Sprouse, C., Lecavalier, L., Leonard, E., Gadow, K., … Chez, M. (2004). Outcome measures for clinical drug trials in autism. CNS Spectrums, 9(1), 36–47. https://doi.org/10.1017/S1092852900008348 CrossRefPubMedPubMedCentralGoogle Scholar
  4. Aman, M. G. (2012a). Aberrant Behavior Checklist: Current identity and future developments. Journal of Clinical and Experiment Pharmacology, 2, e114. https://doi.org/10.4172/2161-1459.1000e114 CrossRefGoogle Scholar
  5. Aman, M.G. (2012b, June) Annotated biography on the Aberrant Behavior Checklist (ABC). Unpublished Manuscript. Columbus, OH: The Ohio State University.Google Scholar
  6. Aman, M. G., Alvarez, N., Benefield, W., Crismon, M. L., Green, G., King, B. H., … Szymanski, L. (2002). Treatment of psychiatric and behavioral problems in mental retardation. American Journal on Mental Retardation, 105, 159–228.Google Scholar
  7. Aman, M. G., Burrow, W. H., & Wolford, P. L. (1995). The Aberrant Behavior Checklist—Community: Factor validity and effect of subject variables for adults in group homes. American Journal on Mental Retardation, 100, 283–292.PubMedPubMedCentralGoogle Scholar
  8. Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., … Sukhodolsky, D. D. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child & Adolescent Psychiatry, 48(12), 1143–1154.CrossRefGoogle Scholar
  9. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.Google Scholar
  10. Aman, M. G., Tassé, M. J., Rojahn, J., & Hammer, D. (1996). The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities, 17, 41–57.PubMedCrossRefPubMedCentralGoogle Scholar
  11. Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Developmental Disorders, 19(2), 227–239. https://doi.org/10.1007/BF02211843 CrossRefPubMedPubMedCentralGoogle Scholar
  12. Arnold, L. E. (1993). Clinical pharmacological issues in treating psychiatric disorders of patients with mental retardation. Annals of Clinical Psychiatry, 5(3), 189–197.PubMedCrossRefPubMedCentralGoogle Scholar
  13. Arnold, L. E., Aman, M. G., Cook, A. M., Witwer, A. N., Hall, K. L., Thompson, S., & Ramadan, Y. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45(10), 1196–1205.PubMedCrossRefPubMedCentralGoogle Scholar
  14. Arnold, L. E., Aman, M. G., Martin, A., Collier-Crespin, A., Vitiello, B., Tierney, E., … Klin, A. (2000). Assessment in multisite randomized clinical trials of patients with autistic disorder: The Autism RUPP Network. Journal of Autism and Developmental Disorders, 30(2), 99–111.PubMedCrossRefPubMedCentralGoogle Scholar
  15. Ballinger, C. T., Varley, C. K., & Nolen, P. A. (1984). Effects of methylphenidate on reading in children with ADD. American Journal of Psychiatry, 141, 1590–1593.PubMedCrossRefPubMedCentralGoogle Scholar
  16. Barkley, R. A., McMurray, M. B., Edelbrock, C. S., & Robbins, K. (1990). Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic, placebo-controlled evaluation. Pediatrics, 86(2), 184–192.PubMedPubMedCentralGoogle Scholar
  17. Benedetto-Nasho, E., & Tannock, R. (1999). Math computation performance and error patterns of children with attention deficit hyperactivity disorder. Journal of Attention Disorders, 3, 121–134.CrossRefGoogle Scholar
  18. Biederman, J., Mick, E., Faraone, S. V., Wozniak, J., Spencer, T., & Pandina, G. (2006). Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: A post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. Clinical Therapy, 28, 794–800.CrossRefGoogle Scholar
  19. Brass, E. P. (2010). The gap between clinical trials and clinical practice: The use of pragmatic clinical trials to inform regulatory decision making. Clinical Pharmacology & Therapeutics, 87(3), 351–355.CrossRefGoogle Scholar
  20. Buchsbaum, M., Hollander, E., Haznedar, M., Tong, C., Spiegal-Cohen, J., Wei, T., … Cartwright, C. (2001). Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: A pilot study. International Journal of Neuropsychopharmacology, 4(2), 119–125.PubMedCrossRefPubMedCentralGoogle Scholar
  21. Buitelaar, J. K., van der Gaag, R. J., Cohen-Kettenis, P., & Melman, C. T. (2001). A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with sub average cognitive abilities. The Journal of Clinical Psychiatry, 64(2), 239–248.CrossRefGoogle Scholar
  22. Busner, J., & Targum, S. D. (2007). The clinical global impressions scale. Psychiatry, 4(7), 28–37.PubMedPubMedCentralGoogle Scholar
  23. Carlson, G., Pokrzywinski, J., Uran, K., & Valdovinos, M. (2012). The use of reinforcer assessments in evaluating psychotropic medication effects. Journal of Developmental and Physical Disabilities, 24, 515–528.CrossRefGoogle Scholar
  24. Cooper, J. O., Heron, T. E., & Heward, W. L. (2007). Applied behavior analysis. Upper Saddle River, NJ: Pearson/Merrill – Prentice Hall.Google Scholar
  25. Danvo, S. E., Tervo, R., Meyers, S., & Symons, F. J. (2012). Using functional analysis methodology to evaluate effects of an atypical antipsychotic on severe problem behavior. Journal of Mental Health Research in Intellectual Disabilities, 5, 286–308.CrossRefGoogle Scholar
  26. de Kuijper, G. M., & Hoekstra, P. J. (2017). Physician’s reasons on long-term use of antipsychotics. Journal of Intellectual Disability Research, 61(10), 899–908.PubMedCrossRefPubMedCentralGoogle Scholar
  27. Edelbrock, C. S. (1985). Child behavior rating form. Psychopharmacology Bulletin, 21, 835–837.Google Scholar
  28. Farmer, C., & Aman, M. G. (2017). Aberrant behavior checklist. Encyclopedia of Autism Spectrum Disorders, 1–8.Google Scholar
  29. FDA (February 1, 2016). What is a serious adverse event? Retrieved from: https://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm.
  30. Findling, R. L., Aman, M. G., Eerdekens, M., Derivan, A., Llyons, B., & The Risperidone Disruptive Behavior Study Group. (2004). Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. The American Journal of Psychiatry, 161(4), 677–684.PubMedCrossRefGoogle Scholar
  31. Findling, R. L., Reed, M. D., O’Riordan, M. A., Demeter, C. A., Stansbrey, R. J., & McNamara, N. K. (2006). Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 792–800.PubMedCrossRefGoogle Scholar
  32. Findling, R. L., Reed, M. D., O’Riordan, M. A., Demeter, C. A., Stansbrey, R. J., & McNamara, N. K. (2007). A 26-week open-label study of quetiapine in children with conduct disorder. Journal of Child and Adolescent Psychopharmacology, 17, 1–9.PubMedCrossRefGoogle Scholar
  33. Gagliano, A., Germano, E., Pustorino, G., Impallomeni, C., D’Arrigo, C., Calamoneri, F., & Spina, E. (2004). Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. Journal of Child and Adolescent Psychopharmacology, 14(1), 39–47.PubMedCrossRefGoogle Scholar
  34. Goodman, W. K., Price, L. H., Rasmussen, S. A., Mazure, C., Fleischmann, R. L., Hill, C. L., … Charney, D. S. (1989). The Yale–Brown obsessive compulsive scale: I. Development, use, and reliability. Archives of General Psychiatry, 46, 1006–1011.PubMedCrossRefGoogle Scholar
  35. Goodman, W. K., Rasmussen, S. A., Price, L. H., & Storch, E. A. (2006). Yale–Brown obsessive-compulsive scale—Second Edition. Unpublished manuscript.Google Scholar
  36. Gordon, C. T., State, R. C., & Nelson, J. E. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50(6), 441–447. https://doi.org/10.1001/archpsyc.1993.01820180039004 CrossRefPubMedPubMedCentralGoogle Scholar
  37. Guy, W. (1976). ECDEU Assessment manual for psychopharmacology, revised, 1976 (pp. 76–338). Rockville, MD: United States Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration.Google Scholar
  38. Hage, A., Banaschewski, T., Buitlaar, J. K., Dijkhuizen, R. M., Franke, B., Lythgoe, D. J., … TACTICS Consortium. (2016). Glutamatergic medication in the treatment of obsessive compulsive disorder and autism spectrum disorder- study protocol for a randomized controlled trial. Trials, 17(141), 1–16.Google Scholar
  39. Handen, B. L., Aman, M. G., Arnold, L. E., Hyman, S. L., Tumuluru, R. V., Lecavalier, L., … Silverman, L. B. (2015). Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 54(11), 905–915.CrossRefGoogle Scholar
  40. Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30(3), 245–255.PubMedCrossRefGoogle Scholar
  41. Hastings, R. P., Brown, T., Mount, R. H., & Cormack, K. F. M. (2001). Exploration of psychometric properties of the developmental behavior checklist. Journal of Autism and Developmental Disorders, 31(4), 423–431. https://doi.org/10.1023/A:1010668703948 CrossRefPubMedGoogle Scholar
  42. Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., … Cook, E. H. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child & Adolescent Psychopharmacology, 15(4), 682–692.CrossRefGoogle Scholar
  43. Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., & Iyengar, R. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30(3), 582–589.PubMedCrossRefGoogle Scholar
  44. Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., … Settipani, B. A. (2012). A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry, 169(3), 292–299.PubMedCrossRefGoogle Scholar
  45. Houghton, R., Ong, R. C., & Bolognani, F. (2017). Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States. Autism Research, 10, 2037–2047. https://doi.org/10.1002/aur.1848 CrossRefPubMedGoogle Scholar
  46. Iwata, B. A., Dorsey, M. F., Slifer, K. J., Bauman, K. E., & Richman, G. S. (1994). Toward a functional analysis of self-injury. Journal of Applied Behavior Analysis, 27, 197–209.PubMedPubMedCentralCrossRefGoogle Scholar
  47. Johnson, C. R., Handen, B. L., Butter, E., Wagner, A., Mulick, J., Sukhodolsky, D. G., … Scahill, L. (2007). Development of a parent training program for children with pervasive developmental disorders. Behavior Intervention, 22, 201–221.CrossRefGoogle Scholar
  48. Johnston, J. M., Pennypacker, H. S., & Green, G. (2010). Strategies and tactics of behavioral research. Abingdon-on-Thames, UK: Routledge.Google Scholar
  49. Kaat, A. J., Lecavalier, L., & Aman, M. G. (2014). Validity of the aberrant behavior checklist in children with autism spectrum disorder. Journal of Autism Developmental Disorders, 44(5), 1103–1116. https://doi.org/10.1007/s10803-013-1970-0 CrossRefPubMedGoogle Scholar
  50. Kalachnik, J. E. (1999). Measuring side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities. Developmental Disabilities Research Reviews, 5(4), 348–359.CrossRefGoogle Scholar
  51. Kalachnik, J. E., & Sprague, R. L. (1993). The Dyskinesia Identification System Condensed User Scale (DISCUS): Reliability, validity, and a total cut-off for mentally ill and mentally retarded populations. Journal of Clinical Psychology, 49, 177–189.PubMedPubMedCentralGoogle Scholar
  52. Karabekiroglu, K., & Aman, M. (2008). Validity of the aberrant behavior checklist in a clinical sample of toddlers. Child Psychiatry and Human Development, 40, 99–110. https://doi.org/10.1007/s10578-008-0108-7 CrossRefPubMedGoogle Scholar
  53. Kearney, A. J. (2008). Understanding applied behavior analysis: An introduction to ABA for parents, teachers, and other professionals. Philadelphia: Jessica Kingsley Publishers.Google Scholar
  54. King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., … Ritz, L. (2009). Lack of efficacy in citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590. https://doi.org/10.1001/archgenpsychiatry.2009.30 CrossRefPubMedPubMedCentralGoogle Scholar
  55. Klotz, U. (2007). The role of pharmacogenetics in the metabolism of antiepileptic drugs. Clinical Pharmacokinetics, 46(4), 271–279.PubMedCrossRefGoogle Scholar
  56. Langworthy-Lam, K. S., Aman, M. G., & Van Bourgondien, M. E. (2002). Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology, 12(4), 311–321.PubMedCrossRefGoogle Scholar
  57. LaRue, R. H., Northup, J., Baumeister, A. A., Hawkins, M. F., Seale, L., Williams, T., & Ridgway, A. (2008). An evaluation of stimulant medication on the reinforcing effects of play. Journal of Applied Behavior Analysis, 41, 143–147.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Lecavalier, L., Aman, M. G., Hammer, D., Stocia, W., & Mathews, G. L. (2004). Factor analysis of the Nisonger Child Behavior Rating Scale Form in children with autism spectrum disorders. Journal of Autism and Developmental Disorders, 34(6), 709–721.PubMedCrossRefGoogle Scholar
  59. Ledford, J. R., Lane, J. D., & Gast, D. L. (2018). Dependent variables, measurement, and reliability. In J. R. Ledford & D. L. Gast (Eds.), Single case research methodology: Applications in special education and behavioral sciences (3rd ed., pp. 97–132). New York, NY: Routledge.CrossRefGoogle Scholar
  60. LoVullo, S. V., & Matson, J. L. (2009). Comorbid psychopathology in adults with autism spectrum disorders in intellectual disabilities. Research in Developmental Disabilities, 30, 1288–1296.PubMedCrossRefPubMedCentralGoogle Scholar
  61. Madsen, E. K., Peck, J. A., & Valdovinos, M. G. (2016). A review of research on direct-care staff data collection regarding the severity and function of challenging behavior in individuals with intellectual and developmental disabilities. Journal of Intellectual Disabilities, 20, 296–306.PubMedCrossRefPubMedCentralGoogle Scholar
  62. Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008). Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121(3), e441–e448.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 48(11), 1110–1119.CrossRefGoogle Scholar
  64. Marshburn, E. C., & Aman, M. (1992). Factor validity norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. Journal of Autism and Developmental Disorders, 22, 357–373. https://doi.org/10.1007/BF01048240 CrossRefPubMedPubMedCentralGoogle Scholar
  65. Matson, J., & Neal, D. (2009). Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview. Research in Developmental Disabilities, 30, 572–586.PubMedCrossRefPubMedCentralGoogle Scholar
  66. Matson, J. L., & Mahan, S. (2010). Antipsychotic drug side effects for persons with intellectual disability. Research in Developmental Disabilities, 31(6), 1570–1576.PubMedCrossRefPubMedCentralGoogle Scholar
  67. Matson, J. L., Mayville, E. A., Bielecki, J., Barnes, W. H., Bamburg, J. W., & Baglio, C. S. (1998). Reliability of the Matson evaluation of drug side effects scale (MEDS). Research in Developmental Disabilities, 19(6), 501–506.PubMedCrossRefPubMedCentralGoogle Scholar
  68. McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., … McDougle, C. J. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321.PubMedCrossRefPubMedCentralGoogle Scholar
  69. McDougle, C., Naylor, S., Cohen, D., Volkmar, F., Heninger, G., & Price, L. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53(11), 1001–1008.PubMedCrossRefPubMedCentralGoogle Scholar
  70. McDougle, C. J., Holmes, J. P., Bronson, M. R., Anderson, G. M., Volkmar, F. R., Price, L. H., & Cohen, D. (1997). Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of American Academy of Child and Adolescent Psychiatry, 36, 685–693.CrossRefGoogle Scholar
  71. McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., … Shah, B. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162(6), 1142–1148.PubMedCrossRefPubMedCentralGoogle Scholar
  72. Meyer, U. A. (2000). Pharmacogenetics and adverse drug reactions. The Lancet, 356(9242), 1667–1671.CrossRefGoogle Scholar
  73. Mills, E. J., Chan, A. W., Wu, P., Vail, A., Guyatt, G. H., & Altman, D. G. (2009). Design, analysis, and presentation of crossover trials. Trials, 10(1), 27.PubMedPubMedCentralCrossRefGoogle Scholar
  74. Napolitano, D. A., Jack, S. L., Sheldon, J. B., Williams, D. C., McAdam, D. B., & Schroeder, S. R. (1999). Drug-behavior interactions in persons with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5(4), 322–334.CrossRefGoogle Scholar
  75. Nicolson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young children with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 37(4), 372–376. https://doi.org/10.1097/00004583-199804000-00014 CrossRefPubMedPubMedCentralGoogle Scholar
  76. Overall, J. E., & Campbell, M. (1988). Behavioral assessment of psychopathology in children: Infantile autism. Journal of Clinical Psychology, 44(5), 708–716.PubMedCrossRefPubMedCentralGoogle Scholar
  77. Overall, J. E., & Pfefferbaum, B. (1984). A brief scale for rating psychopathology in children. Innovations in Clinical Practice: A Source Book, 3, 257–266.Google Scholar
  78. Owen, R., Sikich, l., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., … Findling, R. L. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533–1540. https://doi.org/10.1542/peds.2008-3782 CrossRefPubMedPubMedCentralGoogle Scholar
  79. Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007). Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 37(2), 367–373.PubMedCrossRefPubMedCentralGoogle Scholar
  80. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347, 314–321.CrossRefGoogle Scholar
  81. Reyes, M., Croonenberghs, J., Augustyns, I., & Eerdekens, M. (2006). Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. Journal of Child and Adolescent Psychopharmacology, 16, 260–272.PubMedCrossRefPubMedCentralGoogle Scholar
  82. Robinson, J. (2013). Children’s psychiatric rating scale. In F. R. Volkmar (Ed.), Encyclopedia of autism spectrum disorders. New York, NY: Springer. https://doi.org/10.1007/978-1-4419-1698-3 CrossRefGoogle Scholar
  83. Rojahn, J., Rowe, E. W., Macken, J., Gray, A., Delitta, D., Booth, A., & Kimbrell, K. (2010). Psychometric evaluation of the Behavior Problems Inventory-01 and the Nisonger Child Behavior Rating Form with children and adolescents. Journal of Mental Health Research in Intellectual Disabilities, 3(1), 28–50. https://doi.org/10.1080/19315860903558168 CrossRefGoogle Scholar
  84. Scahill, L., McDougle, C. J., Aman, M. G., Johnson, C., Handen, B., Bearss, K., … Stigler, K. A. (2012). Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems. Journal of the American Academy of Child & Adolescent Psychiatry, 51(2), 136–146.CrossRefGoogle Scholar
  85. Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K., … Leckman, J. F. (1997). Children’s Yale-Brown obsessive compulsive scale: Reliability and validity. Journal of American Academy of Child and Adolescent Psychiatry, 36, 844–852.CrossRefGoogle Scholar
  86. Schall, C. (2002). A consumer’s guide to monitoring psychotropic medication for individuals with autism spectrum disorders. Focus on Autism and Other Developmental Disabilities, 17(4), 229–235.CrossRefGoogle Scholar
  87. Schroeder, S. R., Hellings, J. A., & Courtemanche, A. B. (2013). How to make effective evaluation of psychotropic drug effects in people with developmental disabilities and self-injurious behavior. In Handbook of crisis intervention and developmental disabilities (pp. 299–316). New York: Springer.CrossRefGoogle Scholar
  88. Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634–e641.PubMedCrossRefPubMedCentralGoogle Scholar
  89. Sibley, M. H., Kuriyan, A. B., Evans, S. W., Waxmonsky, J. G., & Smith, B. H. (2014). Pharmacological and psychosocial treatments for adolescents with ADHD: An updated systematic review of the literature. Clinical Psychology Review, 34(3), 218–232.PubMedCrossRefPubMedCentralGoogle Scholar
  90. Singh, N. N., Singh, A. N., Lancioni, G. E., & Adkins, A. D. (2010). Pharmacological adjuncts. In Handbook of clinical psychology competencies (pp. 1619–1653). New York, NY: Springer.Google Scholar
  91. Sleister, H. M., & Valdovinos, M. G. (2011). Why research on the pharmacogenetics of atypical antipsychotic-induced weight gain in individuals with intellectual disabilities is warranted. Journal of Mental Health Research in Intellectual Disabilities, 4(2), 65–78.CrossRefGoogle Scholar
  92. Smith, T., Sharp, S., Manzardo, A. M., & Butler, M. G. (2015). Pharmacogenetics informed decision making in adolescent psychiatric treatment: A clinical case report. International Journal of Molecular Sciences, 16(3), 4416–4428.PubMedPubMedCentralCrossRefGoogle Scholar
  93. Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S., & Carroll, A. (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 1026–1036.CrossRefGoogle Scholar
  94. Sprague, R. L., & Werry, J. S. (1971). Methodology of psychopharmacological studies with the retarded. International Review of Research in Mental Retardation, 5, 147–219.CrossRefGoogle Scholar
  95. Storch, E. A., Rasmussen, S. A., Price, L. H., Larson, M. J., Murphy, T. K., & Goodman, W. K. (2010). Development and psychometric evaluation of the Yale-Brown obsessive-compulsive scale-second edition. Psychological Assessment, 22(2), 223–232.PubMedCrossRefPubMedCentralGoogle Scholar
  96. Stortz, J. N., Lake, J. K., Cobigo, V., Ouellette-Kuntz, H. M., & Lunsky, Y. (2014). Lessons learned from our elders: How to study polypharmacy in populations with intellectual and developmental disabilities. Intellectual and Developmental Disabilities, 52(1), 60–77.PubMedCrossRefPubMedCentralGoogle Scholar
  97. Straetmans, J. M., van Schrojenstein Lantman-de, H. M., Schellevis, F. G., & Dinant, G. J. (2007). Health problems of people with intellectual disabilities: The impact for general practice. British Journal of General Practice, 57(534), 64–66.PubMedPubMedCentralGoogle Scholar
  98. Tasse, J. M., Aman, M. G., Hammer, D., & Rojhan, J. (1996). The Nisonger Child Behavior Rating Form: Age and gender effects and norms. Research in Developmental Disabilities, 17(1), 59–75.PubMedCrossRefPubMedCentralGoogle Scholar
  99. Thompson, T., Zarcone, J., & Symons, F. (2004). Methodological issues in psychopharmacology for individuals with intellectual and developmental disabilities. In E. Emerson, C. Hatton, T. Parmeter, & T. Thompson (Eds.), International handbook of applied research in intellectual disabilities (pp. 549–580). Chichester: Wiley.CrossRefGoogle Scholar
  100. Tsai, L. Y. (2000). Children with autism spectrum disorder: Medicine today and in the new millennium. Focus on Autism and Other Developmental Disabilities, 15, 138–145.CrossRefGoogle Scholar
  101. Turgay, A., Binder, C., Snyder, R., & Fisman, S. (2002). Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics, 110(3), 1–12.CrossRefGoogle Scholar
  102. Unwin, G. L., & Deb, S. (2011). Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: A systematic review. Research in Developmental Disabilities, 32, 2121–2133.PubMedCrossRefPubMedCentralGoogle Scholar
  103. US Food and Drug Administration (2017). Precision medicine initiative. Retrieved January 4, 2018 from https://www.fda.gov/ScienceResearch/SpecialTopics/PrecisionMedicine/default.htm
  104. Valdovinos, M. G., Henninger-McMahon, M., Schieber, E., Beard, L., & Haas, A. (2016). Assessing the impact of psychotropic medication changes on challenging behavior of individuals with intellectual disabilities. International Journal of Developmental Disabilities, 62, 200–211.PubMedPubMedCentralCrossRefGoogle Scholar
  105. Valdovinos, M. G., Nelson, S. M., Kuhle, N. L., & Dierks, A. M. (2009). Using analogue functional analysis to measure variations in problem behavior rate and function after psychotropic medication changes: A clinical demonstration. Journal of Mental Health Research in Intellectual Disabilities, 2, 279–293.CrossRefGoogle Scholar
  106. Van Bellinghen, M., & De Troch, C. (2001). Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology, 11, 5–13.PubMedCrossRefPubMedCentralGoogle Scholar
  107. Van der Oord, S., Prins, P. J., Oosterlaan, J., & Emmelkamp, P. M. (2008). Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: A meta-analysis. Clinical Psychology Review, 28(5), 783–800.PubMedCrossRefPubMedCentralGoogle Scholar
  108. Volkmar, F., Siegel, M., Woodbury-Smith, M., King, B., McCracken, J., & State, M. (2014). Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 53(2), 237–257.CrossRefGoogle Scholar
  109. Wasserman, S., Iyendar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostuo, E., … Hollander, E. (2006). Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebo-controlled study. International Clinical Psychopharmacology, 21, 363–3667.PubMedCrossRefPubMedCentralGoogle Scholar
  110. Wu, M. S., McGuire, J. F., Arnold, E. B., Lewin, A. B., Murphy, T. K., & Storch, E. A. (2014). Psychometric properties of the Children’s Yale-Brown obsessive compulsive scale in youth with autism spectrum disorders and obsessive-compulsive symptoms. Child Psychiatry and Human Development, 45, 201–211.PubMedCrossRefPubMedCentralGoogle Scholar
  111. Zarcone, J., Napolitano, D., & Valdovinos, M. (2008). Measurement of problem behavior during medication evaluations. Journal of Intellectual Disability Research, 52(12), 1015–1028.PubMedCrossRefPubMedCentralGoogle Scholar
  112. Zarcone, J. R., Hellings, J. A., Crandall, K., Reese, R. M., Marquis, J., Fleming, K., … Schroeder, S. R. (2001). Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. American Journal on Mental Retardation, 106(6), 525–538.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Jennifer Zarcone
    • 1
    Email author
  • Annette Griffith
    • 2
  • Chrystal Jansz Rieken
    • 2
  1. 1.May InstituteRandolphUSA
  2. 2.The Chicago School of Professional PsychologyChicagoUSA

Personalised recommendations